SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Scienture Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.92−0.44 (-13.10%)
Close on Oct 19, 2026
- Market cap
- $115.68M
- P/E (TTM)
- –
- Dividend yield
- –
Scienture Holdings, Inc. revenue by segment
By business segment
| Revenue | TTM Q1 25 | TTM Q4 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integra [Member] | $146.90K | $136.64K | $1.36M | – | – | – | – | – | – | – | – | – | 100.0% |
| Trxade, Inc.[Member] | – | – | $6.40M | $6.10M | $5.77M | $5.50M | $5.44M | $5.27M | $5.20M | $5.07M | $4.92M | $4.93M | – |
| Community Specialty Pharmacy LLC [Member] | – | – | – | – | $1.25M | $1.22M | $1.18M | $1.27M | $1.38M | $1.52M | $1.65M | $1.65M | – |
| Integra Pharma LLC [Member] | – | – | – | – | $2.35M | $3.66M | $4.75M | $4.69M | $4.78M | $3.42M | $3.25M | $2.84M | – |
| Other Segments [Member] | – | – | $19.20K | – | $50.71K | $75.30K | $60.29K | $75.10K | $94.45K | $68.29K | $62.02K | $70.59K | – |
By product or service
| Revenue | TTM Q1 25 | TTM Q4 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | – | – | $1.85M | $2.04M | $2.35M | – | $4.75M | – | – | – | – | – | – |
| Service Revenue [Member] | – | – | $6.42M | – | – | – | $5.50M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Scienture's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.